PANORAMA V1.0 15Aug2016
Research type
Research Study
Full title
PANORAMA: Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes in Patients with Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
IRAS ID
216431
Contact name
Pieter Postmus
Contact email
Sponsor organisation
AstraZeneca
Clinicaltrials.gov Identifier
229386, PAREXEL International
Duration of Study in the UK
3 years, 3 months, 17 days
Research summary
This study will assess molecular testing, treatment patterns, and associated clinical outcomes among patients with Epidermal Growth Factor Receptor(EGFR) mutation-positive locally advanced or metastatic Non Small Cell Lung Cancer (NSCLC) who have progressed while on or after receiving EGFR- Tyrosine Kinase inhibitor(TKI) therapy (primary cohort).
Additionally, the study also aims to evaluate molecular testing, treatment patterns, and associated clinical outcomes in a secondary cohort of newly diagnosed patients with locally advanced or metastatic NSCLC who are treatment naïve or patients who were diagnosed at an earlier stage but have progressed to metastatic NSCLC during the selection period.
This study is descriptive in nature and does not attempt to test any specific a priori hypotheses.
REC name
London - Chelsea Research Ethics Committee
REC reference
16/LO/2128
Date of REC Opinion
8 Dec 2016
REC opinion
Further Information Favourable Opinion